Company
InDex Pharmaceuticals Holding AB
Headquarters: Solna, Sweden
Employees: 9
Market Cap
kr136.4 Million
SEK as of Jan. 1, 2024
US$13.5 Million
InDex Pharmaceuticals Holding AB Categories
Sweden Healthcare BiotechnologySweden Healthcare Sweden Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in late-stage clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for use in the treatment of various immunological diseases. The company was founded in 2015 and is headquartered in Solna, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
InDex Pharmaceuticals Holding AB has the following listings and related stock indices.
Stock: OMX: INDEX wb_incandescent
Stock: FSX: 1NP wb_incandescent